0001078799 false 12/31 2021 Q2 0001078799 2021-01-01 2021-06-30 0001078799 2021-08-19 0001078799 2021-06-30 0001078799 2020-12-31 0001078799 us-gaap:PreferredClassAMember 2021-06-30 0001078799 us-gaap:PreferredClassAMember 2020-12-31 0001078799 us-gaap:PreferredClassBMember 2021-06-30 0001078799 us-gaap:PreferredClassBMember 2020-12-31 0001078799 2021-04-01 2021-06-30 0001078799 2020-04-01 2020-06-30 0001078799 2020-01-01 2020-06-30 0001078799 MCOA:PreferredStockClassAMember 2019-12-31 0001078799 MCOA:PreferredStockClassBMember 2019-12-31 0001078799 us-gaap:CommonStockMember 2019-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2019-12-31 0001078799 MCOA:StockSubcriptionsMember 2019-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001078799 us-gaap:RetainedEarningsMember 2019-12-31 0001078799 2019-12-31 0001078799 MCOA:PreferredStockClassAMember 2020-01-01 2020-06-30 0001078799 MCOA:PreferredStockClassBMember 2020-01-01 2020-06-30 0001078799 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2020-01-01 2020-06-30 0001078799 MCOA:StockSubcriptionsMember 2020-01-01 2020-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001078799 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001078799 MCOA:PreferredStockClassAMember 2020-06-30 0001078799 MCOA:PreferredStockClassBMember 2020-06-30 0001078799 us-gaap:CommonStockMember 2020-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2020-06-30 0001078799 MCOA:StockSubcriptionsMember 2020-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001078799 us-gaap:RetainedEarningsMember 2020-06-30 0001078799 2020-06-30 0001078799 MCOA:PreferredStockClassAMember 2020-12-31 0001078799 MCOA:PreferredStockClassBMember 2020-12-31 0001078799 us-gaap:CommonStockMember 2020-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2020-12-31 0001078799 MCOA:StockSubcriptionsMember 2020-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001078799 us-gaap:RetainedEarningsMember 2020-12-31 0001078799 MCOA:PreferredStockClassAMember 2021-01-01 2021-06-30 0001078799 MCOA:PreferredStockClassBMember 2021-01-01 2021-06-30 0001078799 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2021-01-01 2021-06-30 0001078799 MCOA:StockSubcriptionsMember 2021-01-01 2021-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001078799 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001078799 MCOA:PreferredStockClassAMember 2021-06-30 0001078799 MCOA:PreferredStockClassBMember 2021-06-30 0001078799 us-gaap:CommonStockMember 2021-06-30 0001078799 MCOA:CommonStockToBeIssuedMember 2021-06-30 0001078799 MCOA:StockSubcriptionsMember 2021-06-30 0001078799 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001078799 us-gaap:RetainedEarningsMember 2021-06-30 0001078799 MCOA:SparrowtechIncMember 2009-10-01 2009-10-31 0001078799 us-gaap:PropertyPlantAndEquipmentMember 2021-01-01 2021-06-30 0001078799 us-gaap:PropertyPlantAndEquipmentMember srt:MinimumMember 2021-01-01 2021-06-30 0001078799 us-gaap:PropertyPlantAndEquipmentMember srt:MaximumMember 2021-01-01 2021-06-30 0001078799 MCOA:OperatingSegmentMember 2021-01-01 2021-03-31 0001078799 MCOA:OperatingSegmentMember 2021-04-01 2021-06-30 0001078799 MCOA:OperatingSegmentMember 2021-01-01 2021-06-30 0001078799 MCOA:OperatingSegmentMember 2020-01-01 2020-03-31 0001078799 MCOA:OperatingSegmentMember 2020-04-01 2020-06-30 0001078799 MCOA:OperatingSegmentMember 2020-01-01 2020-06-30 0001078799 us-gaap:LeaseAgreementsMember 2019-06-29 2019-07-02 0001078799 us-gaap:ComputerEquipmentMember 2021-06-30 0001078799 us-gaap:ComputerEquipmentMember 2020-12-31 0001078799 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001078799 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001078799 us-gaap:MachineryAndEquipmentMember 2021-06-30 0001078799 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember 2017-03-16 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember 2017-11-06 0001078799 2017-01-01 2017-12-31 0001078799 2018-01-01 2018-03-31 0001078799 2018-04-01 2018-06-30 0001078799 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember 2016-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2016-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2016-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2016-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2016-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2016-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2016-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2016-12-31 0001078799 MCOA:InvestmentMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2017-01-01 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2017-01-01 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2017-01-01 2017-12-31 0001078799 MCOA:InvestmentMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2017-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:GlobalHempMember 2017-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2017-12-31 0001078799 MCOA:InvestmentMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2018-01-01 2018-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2018-01-01 2018-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2018-01-01 2018-12-31 0001078799 MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2018-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2018-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2018-12-31 0001078799 MCOA:InvestmentMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-01-01 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-01-01 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:GlobalHempMember 2019-03-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2019-06-30 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:GlobalHempMember 2019-06-30 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2019-09-30 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2019-10-01 2019-12-31 0001078799 MCOA:InvestmentMember 2019-10-01 2019-12-31 0001078799 MCOA:GlobalHempGroupMember 2019-10-01 2019-12-31 0001078799 MCOA:VivabudsMember 2019-10-01 2019-12-31 0001078799 MCOA:NaturalPlantMember 2019-10-01 2019-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-10-01 2019-12-31 0001078799 MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2019-12-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember 2020-01-01 2020-03-31 0001078799 MCOA:GlobalHempGroupMember 2020-01-01 2020-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-03-31 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2020-03-31 0001078799 MCOA:InvestmentMember 2020-04-01 2020-06-30 0001078799 MCOA:GlobalHempGroupMember 2020-04-01 2020-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-04-01 2020-06-30 0001078799 us-gaap:ShortTermInvestmentsMember MCOA:MoneyTracMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-06-30 0001078799 MCOA:MoneyTracMember 2020-06-30 0001078799 MCOA:InvestmentMember 2020-07-01 2020-09-30 0001078799 MCOA:GlobalHempGroupMember 2020-07-01 2020-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-09-30 0001078799 MCOA:MoneyTracMember 2020-09-30 0001078799 us-gaap:ShortTermInvestmentsMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember 2020-10-01 2020-12-31 0001078799 MCOA:GlobalHempGroupMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-12-31 0001078799 us-gaap:ShortTermInvestmentsMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2020-12-31 0001078799 MCOA:MoneyTracMember 2020-12-31 0001078799 MCOA:InvestmentMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-01-01 2021-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-03-31 0001078799 us-gaap:ShortTermInvestmentsMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2021-03-31 0001078799 MCOA:MoneyTracMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2021-04-01 2021-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempGroupMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:BenihempMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:MoneyTracMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:BougainvilleVentuesMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:GateCResearchMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-06-30 0001078799 us-gaap:ShortTermInvestmentsMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:GlobalHempMember 2021-06-30 0001078799 MCOA:MoneyTracMember 2021-06-30 0001078799 2020-03-31 0001078799 2019-09-30 0001078799 2019-06-30 0001078799 2019-03-31 0001078799 2018-12-31 0001078799 2017-12-31 0001078799 MCOA:ConvertibleNotePayableElevenMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableElevenMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableTwelveMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableTwelveMember 2020-12-31 0001078799 MCOA:ConvertiblenotepayableLabrysMember 2021-06-30 0001078799 MCOA:ConvertiblenotepayableLabrysMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableFifteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableFifteenMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableGenevaRothMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableGenevaRothMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableSeventeenMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableSeventeenMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableDutchessCapitalPartnersMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableDutchessCapitalPartnersMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableRedstartHLDGSMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableRedstartHLDGSMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableGWHoldingsMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableGWHoldingsMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableStGeorgeMember 2021-06-30 0001078799 MCOA:ConvertibleNotePayableStGeorgeMember 2020-12-31 0001078799 MCOA:LabrysMember 2021-06-30 0001078799 MCOA:PowerUpLendingMember 2021-06-30 0001078799 MCOA:PowerUpLendingMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember 2019-03-24 2019-03-25 0001078799 MCOA:ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember 2019-10-01 2019-12-31 0001078799 MCOA:OdysseyFundingLLCMember 2021-06-30 0001078799 MCOA:OdysseyFundingLLCMember 2020-12-31 0001078799 MCOA:PaladinAdvisorsLLCMember 2021-06-30 0001078799 MCOA:PaladinAdvisorsLLCMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2019-12-19 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember 2018-08-28 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember us-gaap:WarrantMember 2018-08-27 2018-08-28 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember 2018-08-27 2018-08-28 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableAugustTwentyEightTwoThousandEighteenMember 2021-03-30 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2019-01-29 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2019-01-01 2019-09-30 0001078799 MCOA:ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember us-gaap:WarrantMember 2019-03-25 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember us-gaap:WarrantMember 2019-01-28 2019-01-29 0001078799 MCOA:ConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2019-01-28 2019-01-29 0001078799 MCOA:ConvertibleNotesPayableMarchTwentyFiveTwoThousandNineteenMember 2019-03-25 0001078799 MCOA:ConvertibleNotesPayableDecemberTwentyThreeTwoThousandNineteenMember 2021-06-30 0001078799 MCOA:ConvertibleNotesPayableDecemberTwentyThreeTwoThousandNineteenMember 2020-12-23 0001078799 MCOA:GWHoldingsGroupMember 2020-01-01 2020-01-06 0001078799 2021-02-24 2021-02-26 0001078799 us-gaap:PreferredClassAMember 2021-01-01 2021-06-30 0001078799 us-gaap:PreferredClassBMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockOneMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockTwoMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockThreeMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockFourMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockFiveMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockSixMember 2021-01-01 2021-06-30 0001078799 MCOA:CommonStockOneMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockTwoMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockThreeMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockFourMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockFiveMember 2020-01-01 2020-06-30 0001078799 MCOA:CommonStockSixMember 2020-01-01 2020-06-30 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-06-30 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001078799 MCOA:OfficerAndExecutivesMember 2021-06-30 0001078799 MCOA:OfficerAndExecutivesMember 2020-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2021

 

or

 

  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                          to                          

 

Commission file number: 000-27039

 

MARIJUANA COMPANY OF AMERICA, INC.

(Exact name of registrant as specified in its charter)

 

Utah   98-1246221
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     
633 West Fifth Street, Suite 2826    
Los Angeles, CA   90071
(Address of principal executive offices)   (Zip Code)

 

(888) 777-4362

(Registrant’s telephone number, including area code)

 

1340 West Valley Parkway, Suite 205, Escondido CA 92029

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes    No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes    No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
Non-accelerated Filer   Smaller reporting company
Emerging growth company      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes    No 

 

The number of shares of the issuer’s common stock, $0.001 par value per share, outstanding at August 19, 2021 was 5,405,130,704.

 

 
 
 

 

 

 

    PAGE
PART I. FINANCIAL INFORMATION
      
  ITEM 1.  Financial Statements  4
      
     Condensed consolidated balance sheets as of June 30, 2021 (unaudited) and December 31, 2020 (audited)  4
      
     Condensed consolidated statements of operations for the three and six month ended June 30, 2021 and 2020 (unaudited)  5
      
     Condensed consolidated statement of stockholders’ deficit for the six months ended June 30, 2021 and 2020 (unaudited)  6
      
     Condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 (unaudited)  8
      
     Notes to condensed consolidated financial statements (unaudited)  9
      
  ITEM 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations  45
  ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk  53
  ITEM 4.  Controls and Procedures  53
         
PART II. OTHER INFORMATION   
      
  ITEM 1.  Legal Proceedings  54
  ITEM 1A.  Risk Factors  54
  ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds  55
  ITEM 3.  Defaults Upon Senior Securities  55
  ITEM 4.  Mine Safety Disclosures  55
  ITEM 5.  Other Information  55
  ITEM 6.  Exhibits  56
     SIGNATURES  57
    

 

2 
 
 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

 

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and “would.” For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, plans and objectives of management and markets for our common stock are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

 

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout our most recent Annual Report on Form 10-K and any updates described in our Quarterly Reports on  Form 10-Q and Current Reports on Form 8-K as may be amended, supplemented or superseded from time to time by other reports we file with the U.S. Securities and Exchange Commission (the “SEC”). You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits to the reports we file with the SEC, completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this Quarterly Report on Form 10-Q is accurate as of the date hereof. Because the risk factors in our SEC reports, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this Quarterly Report on Form 10-Q, and particularly our forward-looking statements, by these cautionary statements.

 

 

 

 

 

 

3 
 
 

 PART 1 – FINANCIAL INFORMATION

MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS   

           
    Unaudited    Audited 
    June 30, 2021    Dec 31, 2020 
           
ASSETS          
Current assets:          
Cash  $179,811   $74,503 
Short-term investments   743,200    239,063 
Accounts receivable, net   47,570    8,640 
Inventory   203,898    103,483 
Prepaid insurance         55,783 
Other current assets   93,830    56,121 
  Total current assets   1,268,309    537,593 
           
Property and equipment, net   111,898    6,542 
           
Other assets:          
Long-term investments   2,232,899    1,552,001 
Right-of-use-assets         7,858 
Goodwill   2,989,803       
Security deposit   2,500    2,500 
           
Total assets   6,605,409    2,106,494 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
Current liabilities:          
Accounts payable   706,396    480,877 
Accrued compensation   9,000    79,214 
Accrued liabilities   136,108    401,461 
Notes payable, related parties   20,000    40,000 
Loans payable PPP Stimulus   35,500    35,500 
Convertible notes payable, net of debt discount of $1,122,225 and $808,980, respectively   497,775    1,426,894 
Loans payable - acquisition   100,000       
Contingent liability - acquisition   1,000,000       
Right-of-use liabilities - current portion         7,858 
Subscriptions payable   1,063,977    670,000 
Derivative liability   1,904,016    4,426,057 
  Total current liabilities   

5,472,772

    7,567,861 
           
Total liabilities   

5,472,772

    7,567,861 
           
Stockholders' deficit:          
Preferred stock, $0.001 par value, 50,000,000 shares authorized          
Class A preferred stock, $0.001 par value, 10,000,000 shares designated, 10,000,000 shares issued and outstanding as of June 30, 2021 and December 31, 2020   10,000    10,000 
Class B preferred stock, $0.001 par value, 5,000,000 shares designated, 2,000,000 shares issued and outstanding as of June 30, 2021 and December 31, 2020   2,000    2,000 
Common stock, $0.001 par value; 15,000,000,000 shares authorized; 5,068,524,855 and 3,136,774,861 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively   5,068,525    3,136,775 
Common stock to be issued, 266,164,070 and 11,892,411 shares, respectively   266,164    11,892 
Additional paid in capital   87,581,650    77,687,561 
Accumulated deficit   (91,795,702)   (86,309,595)
  Total stockholders' deficit   

1,132,637

    (5,461,367)
           
Total liabilities and stockholders' deficit  $6,605,409   $2,106,494 

 See the accompanying notes to these unaudited condensed consolidated financial statements

 

4 
 
 

 MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020
UNAUDITED

                     
   For the three months ended  For the Six months ended
   June 30, 2021  June 30, 2020  June 30, 2021  June 30, 2020
REVENUES:            
Sales  $16,880   $77,827   $51,810   $156,474 
Related party sales        5,131         8,303 
Total Revenues   16,880    82,958    51,810    164,777 
                     
Cost of sales   3,301    39,187    28,481    73,392 
                     
Gross profit   13,579    43,771    23,329    91,385 
                     
OPERATING EXPENSES:                    
Depreciation   1,262    1,582    2,653    3,328 
Selling and marketing   155,212    74,212    262,761    200,667 
Payroll and related   132,257    95,644    270,402    196,843 
Stock-based compensation   139,000    536,452    158,900    542,767 
General and administrative   611,970    211,116    1,137,652    415,172 
  Total operating expenses   1,039,701    919,006    1,832,368    1,358,777 
                     
Net loss from operations   (1,026,122)   (875,235)   (1,809,039)   (1,267,392)
                     
OTHER INCOME (EXPENSES):                    
Interest expense, net   (891,783)   (881,945)   (1,992,745)   (1,772,096)
Impairment gain (loss) on joint ventures        7,048         (260,954)
Loss on equity investment   (394,194)   (7,048)   (394,194)   (133,893)
Gain (loss) on change in fair value of derivative liabilities   

696,729

    1,572,964    (1,629,289)   1,142,272 
Unrealized gain (loss) on trading securities   (115,997)        504,137    (13,945)
Loss on sale of trading securities        (2,603)        (2,603)
(Loss) gain on settlement of debt   (96,750)        (164,977)   3,490 
Total other income (expense)   (801,995)   688,416    (3,677,068)   (1,037,729)
                     
Net loss before income taxes   (1,828,117)   (186,819)   (5,486,107)   (2,305,121)
                     
Income taxes (benefit)                    
                     
NET INCOME (LOSS)  $(1,828,117)  $(186,819)  $(5,486,107)  $(2,305,121)
                     
                     
Loss per common share, basic and diluted  $(0.00)  $(0.00)  $(0.00)  $(0.01)
                     
Weighted average number of common shares outstanding, basic and diluted (after stock-split)   4,837,346,227    245,000,528    4,465,632,479    185,851,674 

 See the accompanying notes to these unaudited condensed consolidated financial statements

5 
 
 

MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
UNAUDITED

                                     
   Class A Preferred Stock  Class B Preferred Stock  Common Stock  Common Stock to be issued  Stock  Paid In  Accumulated   
   Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Subcriptions  Capital  Deficit  Total
Balance, December 31, 2019   10,000,000   $10,000         $      77,958,081   $77,958         $     $     $63,467,054   $(74,164,213)  $(10,609,201)
Common stock issued to settle amounts previously accrued                       8,333    8                  $6,692         6,700 
Common stock issued for services rendered                        44,658,333    44,658                   498,108         542,766 
Common stock issued in settlement of convertible notes payable and accrued interest   —                      270,547,861    270,549    43,994,720    43,995         1,216,928         1,531,472 
Converson of related party notes payable                       21,384,103    21,384                   29,229         50,613 
Common stock issued in exchange for exercise of warrants on a cashless basis   —                      51,054,214    51,054    1,000,000    1,000         375,446         427,500 
Common shares issued in settlement of legal case                       3,677,889    3,678                   952,573         956,251 
Reclassification of derivative liabilities to additional paid in capital                                                2,231,014         2,231,014 
Net loss   —            —            —            —                        (2,305,121)   (2,305,121)
Balance, June 30, 2020   10,000,000   $10,000         $      469,288,814   $469,289    44,994,720   $44,995   $     $68,777,044   $(76,469,334)  $(7,168,006)
                                                             

 

 

 

6 
 
 

 

 

 

                                     
   Class A Preferred Stock  Class B Preferred Stock  Common Stock  Common Stock to be issued  Stock  Paid In  Accumulated   
   Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Subcriptions  Capital  Deficit  Total
Balance, December 31, 2020   10,000,000   $10,000    2,000,000   $2,000    3,136,774,841   $3,136,775    11,892,411   $11,892   $     $77,687,561   $(86,309,595)  $(5,461,367)
Common stock issued to settle amounts previously accrued                       —                                        
Issuance of preferred stock to officer   —            —     $      —            —                      $         
Common stock issued for services rendered   —                      21,000,020    21,000    —                 119,900         140,900 
Common stock issued in settlement of convertible notes payable and accrued interest   —                      810,689,880    810,690    —                 930,184          1,740,874 
Issuance of common stock for settlement of liabilities   —                      3,027,031    3,027    (10,892,411)   (10,892)        16,488         8,623 
Issuance of common stock for settlement of liabilities – related parties                       22,500,000    22,500    —                 119,250         141,750 
Common stock issued in exchange for exercise of warrants on a cashless basis   —                      400,000,000    400,000    —                  (400,000)            
Sale of common stock   —                      632,597,599    632,598    —                 726,169          1,358,767 
Issuance of common stock for investments                       41,935,484    41,935                    608,065         650,000
Reclassification of derivative liabilities to additional paid in capital                                                5,975,670         5,975,670 
Debt discount from warrants issued with convertible notes payable                                                446,026         446,026 
Common stock issued for acquisition of business                                 265,164,070    265,164         1,352,337         1,617,501 
Net Loss   —            —            —            —                        (5,486,107)   (5,486,107)
Balance, June 30, 2021   10,000,000   $10,000    2,000,000   $2,000    5,068,524,855   $5,068,525    266,164,070   $266,164   $     $87,581,650   $(91,795,702)  $1,132,637 

 

 See the accompanying notes to these unaudited condensed consolidated financial statements

7 
 
 

 MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
UNAUDITED

           
   2021  2020
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income (loss)  $(5,486,107)  $(2,305,121)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization of debt discount   744,783    1,028,931 
Depreciation and amortization   2,653    3,328 
Impairment loss on equity investment        260,954 
Loss on equity investment   394,194    133,895 
Loss (gain) on change in fair value of derivative liability   1,629,289    (1,142,272)
Interest expense recognized for the excess of fair value of derivative liability over net book value of notes payable at issuance   1,035,115    395,607 
Loss on share inducement and settlement of warrant liability         138,885 
Stock-based compensation   140,900    542,767 
Unrealized (gain) loss on trading securities   (504,137)   27,403 
Loss on settlement of liabilities   168,272       
Changes in operating assets and liabilities:          
Accounts receivable   1,361    9,752 
Inventories   (93,669)   (9,290)
Prepaid expenses and other current assets   37,309    (95,384)
Accounts payable   155,661    145,784 
Accrued expenses and other current liabilities   (67,264)   195,874 
Right-of-use assets   7,858    6,767 
Right-of-use liabilities   (7,858)   (6,885)
Net cash provided by (used in) operating activities   (1,841,640)   (669,005)
           
Cash flows from investing activities:          
Purchases of property and equipment   (107,934)   (1,271)
Payment to establish joint venture   (30,898)      
Acquisition of business   (150,607)      
Net cash provided by (used in) investing activities   (289,439)   (1,271)
           
Cash flows from financing activities:          
Proceeds from issuance of notes payable   1,508,250    442,000 
Proceeds from PPP loan payable         35,500 
Repayments of notes payable   (610,630)      
Repayments to related parties   (20,000)      
Proceeds from sale of common stock   1,358,767       
Net cash provided by (used in) financing activities   2,236,387    477,500 
           
Net increase (decrease) in cash   105,308    (192,776)
           
Cash at beginning of period   74,503    211,765 
           
Cash at end of period  $179,811   $18,989 
    —        
           
           
Supplemental disclosure of cash flow information:          
Cash paid for interest            
Cash paid for taxes            
           
Non cash financing activities:          
Common stock issued in settlement of convertible notes payable  $1,740,874   $1,531,471 
Reclassification of derivative liabilities to additional paid-in capital  $5,975,670   $2,231,014 
Common stock issued for investment  $650,000   $   
Common stock issued to settle liabilities  $8,623   $   
Common stock to be issued for acquisition of business  $1,617,501   $   
Common shares issued in settlement of legal case  $     $956,251 

 See the accompanying notes to these unaudited condensed consolidated financial statements

 

8 
 
 

  

MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2021

(unaudited)

 

NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Marijuana Company of America, Inc. (the “Company”) was incorporated under the laws of the State of Utah in October 1985 under the name Mormon Mint, Inc. The corporation was originally a startup company organized to manufacture and market commemorative medallions related to the Church of Jesus Christ of Latter Day Saints. On January 5, 1999, Bekam Investments, Ltd. acquired one hundred percent of the common shares of the Company and spun the Company off changing its name Converge Global, Inc. From August 13, 1999 until November 20, 2002, the Company focused on the development and implementation of Internet web content and e-commerce applications. In October 2009, in a 30 for 1 exchange, the Company merged with Sparrowtech, Inc. for the purpose of exploration and development of commercially viable mining properties. From 2009 to 2014, we operated primarily in the mining exploration business.

In 2015, the Company changed its business model to a marketing and distribution company for medical marijuana. In conjunction with the change, the Company changed its name to Marijuana Company of America, Inc. At the time of the transition in 2015, there were no remaining assets, liabilities or operating activities of the mining business.

On September 21, 2015, the Company formed H Smart, Inc., a Delaware corporation as a wholly owned subsidiary for the purpose of operating the hempSMART™ brand.

On February 1, 2016, the Company formed MCOA CA, Inc., a California corporation as a wholly owned subsidiary to facilitate mergers, acquisitions and the offering of investments or loans to the Company.

On May 3, 2017, the Company formed Hempsmart Limited, a United Kingdom corporation as a wholly owned subsidiary for the purpose of future expansion into the European market.

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries H Smart, Inc., Hempsmart Limited and MCOA CA, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

The condensed consolidated balance sheet as of December 31, 2020 has been derived from audited financial statements set forth in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on April 14, 2021 (the “Annual Report”).

Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021. These condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020.

NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

The accompanying consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, during the six months ended June 30, 2021, the Company incurred net losses from operations of $5,486,107 and used cash in operations of $1,841,640. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.

The Company's primary source of operating funds for the six months ended June 30, 2021 was from revenue generated from the issuance of convertible and non-convertible debt. The Company has experienced net losses from operations since inception, but expects these conditions to improve in 2021 and beyond as it continues to develop its direct sales and marketing programs; however, no assurance can be provided that the Company will not continue to experience losses in the future. The Company has stockholders' deficiencies as of June 30, 2021 and requires additional financing to fund future operations.

The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding; however, there can be no assurance that the Company will be successful in developing profitable operations or that it will be able to obtain financing on favorable terms, if at all. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

 

9 
 
 

 

 

NOTE 3 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Interim Financial Statements

The unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

Revenue Recognition

For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current GAAP. Revenue is now recognized in accordance with FASB Accounting Standards Codification (“ASC”) Topic 606, Revenue Recognition (“ASC Topic 606”). The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. The Company adopted ASC Topic 606 for its reporting period as of the year ended December 31, 2017, which made its implementation of ASC Topic 606 effective in the first quarter of 2018. The Company decided to implement the modified retrospective transition method to implement ASC Topic 606, with no restatement of the comparative periods presented. Using this transition method, the Company applied the new standards to all new contracts initiated on or after the effective date. The Company also decided to apply this method to any incomplete contracts it determined are subject to ASC Topic 606 prospectively. For the quarter ended June 30, 2021, there were no incomplete contracts. As is more fully discussed below, the Company is of the opinion that none of its contracts for services or products contain significant financing components that require revenue adjustment under ASC Topic 606.

Identification of Our Contracts with Customers 

Contracts included in the Company’s application of ASC Topic 606 for the quarter ended June 30, 2021 consisted solely of sales of the Company’s hempSMART™ products made by its sales associates and by the Company directly through its website. With respect to the Company’s financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 or 2019, or for the quarter ended June 30, 2021.

In accordance with ASC Topic 606, the Company of the opinion that none of its hempSMART™ product sales or offered consulting service, each of which are discussed below, have a significant financing component. The Company’s opinion is based upon the transactional basis for its product sales, with revenue recognized upon customer order, payment and shipment, which occurs concurrently. The Company’s evaluation of the length of time between the customer order, payment and shipping is not a significant financing component because shipment occurs the same day as the order is placed and payment made by the customer. The Company’s evaluation of its consulting services is based upon recognizing revenue as the services are performed for a determinable price per hour. The Company only recognizes revenues as incurred and charge billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.

 

10 
 
 

 

Determination of the Price in Our Sales Contracts

The transaction prices in the Company’s sales contract are the amount of consideration the Company expects to be entitled to for transferring promised hempSMART™ products. The consideration amount is fixed and not variable. The transaction price is allocated to the identified performance obligations in the contract. These allocated amounts are recognized as revenue when or as the performance obligations are fulfilled, which is concurrently upon receipt of payment. There are no future options for a contract when considering and determining the transaction price. The Company excludes amounts third parties will eventually collect, such as sales tax, when determining the transaction price. Since the timing between receiving consideration and transferring goods or services is immediate, the Company’s sales contract do not have a significant financing component, i.e., recognizing revenue at the amount that reflects the cash payment that the customer would have made at the time the goods or services were transferred to them (cash selling price), rather than significantly before or after the goods or services are provided.

Allocation of the Transaction Price of Our Sales Contracts

The Company’s sales contracts are not considered multi-element arrangements which require the fulfillment of multiple performance obligations. Rather, the Company’s sales contracts include one performance obligation in each contract. As such, from the outset, the Company allocates the total consideration to each performance obligation based on the fixed and determinable standalone selling price, which the Company believes is an accurate representation of what the price is in each transaction.

Recognition of Revenue when the Performance Obligation is Satisfied

A performance obligation is satisfied when or as control of the good or service is transferred to the customer. ASC 606-10-20 defines control as “the ability to direct the use of, and obtain substantially all of the remaining benefits from, the asset.” For performance obligations that are fulfilled at a point in time, revenue is recognized at the fulfillment of the performance obligation. As noted above, the Company’s single performance obligation sales contracts are singularly related to its promise to provide the hempSMART™ products to the customer upon receipt of payment, and upon completion, allows the Company to realize revenue under its revenue recognition policy.

With respect to the Company’s offered financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended December 31, 2020 and 2019 or for the quarter ended June 30, 2021. 

Identifying the Performance Obligations in Our Sales Contracts

 

In analyzing the Company’s sales contracts, the Company’s policy is to identify the distinct performance obligations in a sales contract arrangement. In determining the Company’s performance obligations under its sales contracts, the Company considers that the terms and conditions of sales are explicitly outlined in its sales contracts and are so distinct and identifiable within the context of each sales contract, and so are not integrated with other goods, or constitute a modification or customization of other goods in the Company’s contracts, or are highly dependent or highly integrated with other goods in the Company’s sales contracts. Thus, the Company’s performance obligations are singularly related to its promise to provide the hempSMART™ products upon receipt of payment. The Company offers an assurance warranty on its hempSMART™ products that allows a customer to return any hempSMART™ products within 30 days if not satisfied for any reason. Assurance warranties are not identifiable performance obligations since they may be elected at the whim of the customer for any reason. However, the Company does account for returns of purchase prices, if made.

 

11 
 
 

 

Product Sales

Revenue from product sales, including delivery fees, is recognized when (1) an order is placed by the customer; (2) the price is fixed and determinable when the order is placed; (3) the customer is required to and concurrently pays for the product upon order; and (4) the product is shipped. The evaluation of the Company’s recognition of revenue after the adoption of ASC Topic 606 did not include any judgments or changes to judgments that affected the Company’s reporting of revenues since the Company’s product sales, both pre and post adoption of ASC Topic 606 were evaluated using the same standards as noted above, reflecting revenue recognition upon order, payment and shipment, which all occurs concurrently when the order is placed and paid for by the customer, and the product is shipped. Further, given the facts that (1) the Company’s customers exercise discretion in determining the timing of when they place their product order and (2) the price negotiated in the Company’s product sales is fixed and determinable at the time the customer places the order, and there is no delay in shipment, the Company is of the opinion that its product sales do not indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for the Company or the customer under ASC Topic 606.

Consulting Services

The Company also offers professional services for financial accounting, bookkeeping and/or real property management consulting services based on consulting agreements. As of the date of this filing, the Company has not entered into any contracts for any financial accounting, bookkeeping and/or real property management consulting services that have generated reportable revenues as of the years ended December 31, 2020 or 2019 or the quarter ended June 30, 2021. If and when the Company provides these professional services, it would intend and expect the arrangements to be entered into on an hourly fixed fee basis.

For hourly based fixed fee service contracts, the Company intends to utilize and rely upon the proportional performance method, which recognizes revenue as services are performed. Under this method, in order to determine the amount of revenue to be recognized, the Company will calculate the amount of completed work in comparison to the total services to be provided under the arrangement or deliverable. The Company only recognizes revenues as incurred and charges billable hours. Because the Company’s hourly fees for services are fixed and determinable and are only earned and recognized as revenue upon actual performance, the Company is of the opinion that such arrangements are not an indicator of a vendor or customer based significant financing that would materially change the amount of revenue the Company recognizes under the contract or would otherwise contain a significant financing component under ASC Topic 606.  

The Company determined that upon adoption of ASC Topic 606 there were no adjustments converting from ASC 605   to ASC Topic 606 because product sales revenue is recognized upon customer order, payment and shipment, which occurs concurrently, and the Company’s consulting services offered are fixed and determinable and are only earned and recognized as revenue upon actual performance.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Cash

The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash   in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

 

12 
 
 

 

Accounts Receivable 

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis. Thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.

Allowance for Doubtful Accounts

Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of June 30, 2021 and December 31, 2020, allowance for doubtful accounts was $0 and $0, respectively.

Inventories

Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.

Cost of Sales 

Cost of sales is comprised of cost of product sold, packaging, and shipping costs.

Stock-Based Compensation - Employees

The Company accounts for the stock-based compensation in which the Company obtains employee services in share-based payment transactions under the recognition and measurement principles of the fair value recognition provisions of ASC 718-10-30. Pursuant to ASC 718-10-30-6, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  

The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur.  

If the Company is a newly formed corporation or shares of the Company are thinly traded, the use of share prices established in the Company’s most recent private placement based on sales to third parties or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.

The fair value of share options and similar instruments is estimated on the date of grant using a Binomial Option Model option-pricing valuation model.  The ranges of assumptions for inputs are as follows:

 

  Expected term of share options and similar instruments. The expected life of options and similar instruments represents the period of time the options and/or similar instruments are expected to be outstanding. Pursuant to ASC 718-10-50-2(f)(2)(i). the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments.  Pursuant to ASC 718-10-S99-1, it may be appropriate to use the simplified method, i.e., expected term equal the quotient of the vesting term plus the original contractual term divided by two if (i) a company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded; (ii) a company significantly changes the terms of its share option grants or the types of employees that receive share option grants such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term; or (iii) a company has or expects to have significant structural changes in its business such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term. The Company uses the simplified method to calculate expected term of share options and similar instruments as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. 

 

 

13 
 
 

 

 

  Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for it to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. 
  Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments.
  Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. 

Generally, all forms of share-based payments, including stock options, warrants, restricted stock and stock appreciation rights are measured at their fair value on the grant date of the award based on the estimated number of awards that are ultimately expected to vest.

The expense resulting from share-based payments is recorded in general and administrative expense in the statements of operations.

Stock-Based Compensation – Non Employees

Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services

In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation: Improvement to Nonemployee Share-Based Payment Accounting (“Topic 718”s). The ASU supersedes ASC 505-50, Equity-Based Payment to Non-Employment, and expands the scope of the Topic 718 to include stock-based payments granted to non-employees. Under the new guidance, the measurement date and performance and vesting conditions for stock-based payments to non-employees are aligned with those of employees, most notably aligning the award measurement date with the grant date of an award. The new guidance is required to be adopted using the modified retrospective transition approach. The Company adopted the new guidance effective January 1, 2019, and the adoption did not have a material impact on its financial statements and related disclosures.

 

14 
 
 

 

The fair value of share options and similar instruments is estimated on the date of grant using a Binomial option-pricing valuation model.  The ranges of assumptions for inputs are as follows:

 

  Expected term of share options and similar instruments: Pursuant to ASC 718-10-50-2(f)(2)(i), the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and the holder’s expected exercise behavior into the fair value (or calculated value) of the instruments.  The Company uses historical data to estimate the holder’s expected exercise behavior.  If a company is a newly formed corporation or shares of such company are thinly traded, the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as such company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.   
  Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC 718-10-50-2(f)(2)(ii), a thinly-traded or non-public entity that uses the calculated value method shall disclose the reasons why it is not practicable for the company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. 
  Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. 
  Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments.

 

Earnings per Share

Basic earnings per share are calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock outstanding during the period. “Diluted earnings per share” reflects the potential dilution that could occur if the Company’s share-based awards and convertible securities were exercised or converted into common stock. The dilutive effect of the Company’s share-based awards is computed using the treasury stock method, which assumes all share-based awards are exercised and the hypothetical proceeds from exercise are used to purchase common stock at the average market price during the period. The incremental shares (difference between shares assumed to be issued versus purchased), to the extent they would have been dilutive, are included in the denominator of the diluted earnings per share calculation. The dilutive effect of the Company’s convertible preferred stock and convertible debentures is computed using the if-converted method, which assumes conversion at the beginning of the year.

Property and Equipment

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years.

 

15 
 
 

 

Investments 

The Company follows ASC subtopic 321-10, Investments-Equity Securities (“ASC 321-10”) which requires the accounting for an equity security to be measured at fair value with changes in unrealized gains and losses are included in current period operations. Where an equity security is without a readily determinable fair value, the Company may elect to estimate its fair value at cost minus impairment plus or minus changes resulting from observable price changes (See Note 6).

Derivative Financial Instruments

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.

The Company’s free-standing derivatives consisted of conversion options embedded within its issued convertible debt and warrants with anti-dilutive (reset) provisions. The Company evaluated these derivatives to assess their proper classification in the balance sheet using the applicable classification criteria enumerated under GAAP.  The Company determined that certain conversion and exercise options do not contain fixed settlement provisions.  The convertible notes contain a conversion feature and warrants have a reset provision such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the conversion feature and the reset provision which does not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period.   

The Company has adopted a sequencing policy that reclassifies contracts (from equity to assets or liabilities) with the most recent inception date first. Thus, any available shares are allocated first to contracts with the most recent inception dates.

Fair Value of Financial Instruments

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2021 and December 31, 2020. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash and accounts payable. Fair values were assumed to approximate carrying values for cash, accounts payables and short term notes because they are short term in nature.

Advertising

The Company follows the policy of charging the costs of advertising to expense as incurred. The Company charged to operations $168,780 and $44,659 for the six months ended June 30, 2021 and 2020, respectively, as advertising costs.

Segment Information

ASC subtopic Segment Reporting 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein materially represents all of the financial information related to the Company's only material principal operating segment, hempSMART.

16 
 
 

 

hempSMART

STATEMENT OF OPERATIONS

THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020

 

                   
   For the three months ended 

6 Months

Ended

  For the three months ended 

6 Months

Ended

   March 31, 2021  June 30, 2021  June 30, 2021  March 31, 2020  June 30, 2020  June 30, 2020
                   
                   
Revenues  $34,872   $16,537   $51,409   $81,819   $82,958   $164,777 
                               
Cost of Goods Sold   25,032    3,301    28,333    34,205    39,187    73,392 
                               
Gross Profit   9,840    13,236    23,076    47,614    43,771    91,385 
                               
Expense                              
Stock Based Compensation                        17,850    17,850 
Selling and Marketing   97,812    150,881    248,693    101,897    74,356    176,253 
Payroll and Related expenses   53,947    54,864    108,811    18,749    32,113    50,862 
Depreciation Expense   1,391    1,391    2,782    1,746    1,582    3,328 
General and Admin Expenses   55,801    95,864    151,665    67,949    53,911    121,860 
Total Expense   208,951    303,000    511,951    190,341    179,812    370,153 
                               
Net Loss from Operations  $(199,111)  $(289,764)  $(488,875)  $(142,727)  $(136,041)  $(278,768)

Income Taxes

Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized.

 

 

17 
 
 

 

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of June 30, 2021 and 2020, the Company has not recorded any unrecognized tax benefits.

 

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative which aims to reduce unnecessary complexity in GAAP. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2020-06 will have on its financial statements.

 

Recently Issued Accounting Pronouncements Adopted 

 

Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

 

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

 

18 
 
 

 

NOTE 4 – OPERATING LEASE

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires lessees to recognize a lease liability, on a discounted basis, and a right-of-use asset for substantially all leases, as well as additional disclosures regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842), which provides an optional transition method of applying the new lease standard. ASU 2018-11, Topic 842   can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or as permitted by ASU 2018-11, at the beginning of the period in which it is adopted.

 

We adopted this standard using a modified retrospective approach on January 1, 2019. The modified retrospective approach includes a number of optional practical expedients relating to the identification and classification of leases that commenced before the adoption date; initial direct costs for leases that commenced before the adoption date; and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset.

 

The Company elected the package of practical expedients permitted under ASU 2018-11, Leases, allowing it to account for its existing operating lease that commenced before the adoption date as an operating lease under the new guidance without reassessing (i) whether the contract contains a lease; (ii) the classification of the lease; or, (iii) the accounting for indirect costs as defined in ASC 842.  

 

On May 31, 2021, the Company’s operating lease for its office space located at 1340 West Valley Parkway, Suite 205, Escondido, CA 92029 expired and, at that time, the Company fully amortized its right-of-use asset for such lease. On June 1, 2021, the Company entered into an office accommodation agreement whereby it may access a shared office space located at 633 West Fifth Street, Suite 2826, Los Angeles, CA 90071 on a month-to-month basis over a one-year term for a fee of $2,349 per month. In considering its qualitative disclosure obligations under ASC 842-20-50-3, the Company examined its office accommodation agreement for office space that has a fixed monthly fee with no variable payments and no options to extend. The office accommodation agreement creates no tenancy, leasehold, or other real property interest, other than a shared right-of-use. The office accommodation agreement does not provide for terms and conditions granting residual value guarantees by the Company, or any restrictions or covenants imposed for dividends or incurring additional financial obligations by the Company.

 

The Company determined under ASC 2018-11, Leases (Topic 842), due to the short-term nature of the office accommodation agreement, that such agreement met the criteria of ASC 842-20-25-2 and as such it is not necessary to capitalize the office accommodation agreement and fees will be recognized on a monthly straight-line basis. The adoption of this guidance resulted in no significant impact to the Company’s results of operations or cash flows.

 

 

19 
 
 

 

 

NOTE 5 – PROPERTY, MACHINERY AND EQUIPMENT

Property and equipment as of June 30, 2021 and December 31, 2020 is summarized as follows:

          
  

June 30,

2021

 

December 31,

2020

Computer equipment  $23,784   $20,143 
Furniture and fixtures   5,407    5,140 
Machinery   104,102       
Subtotal   133,293    25,283 
Less accumulated depreciation   (21,395)   (18,741)
Property, machinery and equipment, net  $111,898   $6,542 

 

Property, machinery and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. On May 20, 2021, the Company purchased a new cannabis extraction machine which is to be leased to a cannabis distributor and manufacturer called Lynwood-MCOA joint venture. This joint venture is between Cannabis Global Inc. and the Company and pertains to the licensed cannabis operations of Natural Plant Extract of California Inc. in the city of Lynwood, CA. The lease payments are scheduled to commence during the third quarter of 2021.

 

Depreciation expense was $2,653 and $3,328 for the six months ended June 30, 2021 and 2020, respectively. 

 

NOTE 6 – INVESTMENTS 

Bougainville Ventures, Inc. Joint Venture

 

On March 16, 2017, the Company entered into a joint venture agreement with Bougainville Ventures, Inc. (“Bougainville”), a Canadian corporation, to (i) jointly engage in the development and promotion of products in the legalized cannabis industry in Washington State; (ii) utilize Bougainville's high quality cannabis grow operations in the State of Washington, where it claimed to have an ownership interest in real property for use within the legalized cannabis industry; (iii) leverage Bougainville’s agreement with a I-502 Tier 3 license holder to grow cannabis on the site; provide technical and management services and resources including, but not limited to, sales and marketing, agricultural procedures, operations, security and monitoring, processing and delivery, branding, capital resources and financial management; and (iv) optimize collaborative business opportunities. The Company and Bougainville agreed to operate through BV-MCOA Management, LLC, a limited liability company organized in the State of Washington on May 17, 2017.

 

Pursuant to the joint venture agreement, the Company committed to raise not less than $1,000,000 to fund joint venture operations, based upon a funding schedule. The Company also committed to providing branding and systems for the representation of cannabis related products and derivatives comprised of management, marketing and various proprietary methodologies directly tailored to the cannabis industry.

 

The joint venture agreement provided that funding provided by the Company would contribute towards the joint venture’s ultimate purchase of the land consisting of a one-acre parcel located in Okanogan County, Washington, for joint venture operations.

 

As disclosed in the Company’s Current Report on Form 8-K filed with the SEC on December 11, 2017, the Company did not comply with the funding schedule for the joint venture. On November 6, 2017, the Company and Bougainville amended the joint venture agreement to reduce the amount of the Company's commitment from $1,000,000 to $800,000, and also required the Company to issue Bougainville 15 million shares of the Company's restricted common stock. The Company completed its payments pursuant to the amended agreement on November 7, 2017, and on November 9, 2017, issued to Bougainville 15 million shares of restricted common stock. The amended agreement provided that Bougainville would deed the real property to the joint venture within thirty days of its receipt of payment.

 

20 
 
 

 

Thereafter, the Company determined that Bougainville had no ownership interest in the property in Washington State, but rather was a party to a purchase agreement for real property that was in breach of contract for non-payment. Bougainville also did not possess an agreement with a Tier 3 I-502 license holder to grow marijuana on the property. Nonetheless, as a result of funding arranged for by the Company, Bougainville and an unrelated third party, Green Ventures Capital Corp., purchased the land, but did not deed the real property to the joint venture. Bougainville failed to pay delinquent property taxes to Okanogan County, and as a result, as further discussed below, to date, the property has not been deeded to the joint venture.

 

To clarify the respective contributions and roles of the parties, the Company offered to enter into good faith negotiations to revise and restate the joint venture agreement with Bougainville. The Company diligently attempted to communicate with Bougainville to enter into an amended and restated joint venture agreement, and efforts towards satisfying the conditions to complete the subdivision of the land by the Okanogan County Assessor. However, Bougainville failed to cooperate or communicate with the Company in good faith, and failed to pay the delinquent taxes on the real property that would allow for sub-division and the deeding of the real property to the joint venture.

 

On August 10, 2018, the Company advised its independent auditor that Bougainville did not cooperate or communicate with the Company regarding its requests for information concerning the audit of Bougainville’s receipt and expenditures of $800,000 contributed by the Company to the joint venture. Bougainville had a material obligation to do so under the joint venture agreement. The Company believes that some of the funds it paid to Bougainville were misappropriated and that there was self-dealing with respect to those funds. Additionally, the Company believes that Bougainville misrepresented material facts in the joint venture agreement, as amended, including, but not limited to, Bougainville’s representations that: (i) it had an ownership interest in real property that was to be deeded to the joint venture; (ii) it had an agreement with a Tier 3 I-502 cannabis license holder to grow cannabis on the real property; and (iii) that clear title to the real property associated with the Tier 3 I-502 license would be deeded to the joint venture thirty days after the Company made its final funding contribution. As a result, on September 20, 2018, the Company filed a lawsuit against Bougainville, BV-MCOA Management, LLC, Andy Jagpal, Richard Cindric, et al. in Okanogan County Washington Superior Court, case number 18-2-0045324. The Company seeks legal and equitable relief for breach of contract, fraud, breach of fiduciary duty, conversion, recession of the joint venture agreement, an accounting, quiet title to real property in the name of the Company, the appointment of a receiver, the return to treasury of 15 million shares of restricted common stock issued by the Company to Bougainville and treble damages pursuant to the Consumer Protection Act. The Company has filed a lis pendens on the real property. The case is currently in litigation.

 

In connection with the joint venture agreement, the Company recorded a cash investment of $1,188,500 to the joint venture during 2017. This was comprised of a 49.5% ownership of BV-MCOA Management, LLC, and was accounted for using the equity method of accounting. The Company recorded an annual impairment in 2017 of $792,500, reflecting the Company’s percentage of ownership of the net book value of the investment. During 2018, the Company recorded equity losses of $37,673 and $11,043 for the quarters ended March 31, 2018 and June 30, 2018, respectively, and recorded an annual impairment of $285,986 for the year ended December 31, 2018, at which time the Company determined the investment to be fully impaired due to Bougainville’s breach of contract and resulting litigation, as discussed above.

 

21 
 
 

 

Natural Plant Extract

 

On April 15, 2019, the Company entered into a joint venture agreement with Natural Plant Extract of California, Inc. and its   subsidiaries (collectively, “NPE”), to operate a licensed psychoactive cannabis distribution service in California. California legalized THC psychoactive cannabis for medicinal and recreational use on January 1, 2018. On February 3, 2020, the parties terminated the joint venture and entered into a settlement and release agreement (the “Settlement Agreement”). In exchange for a complete release of all claims, the Company and NPE (1) agreed that the Company would reduce its interest in NPE from 20% to 5%; (2) the Company agreed to pay NPE a total of $85,000 as follows: $35,000 concurrent with the execution of the Settlement Agreement, and $25,000 no later than the fifth calendar day for each of the two months following execution of Settlement Agreement; and, (3) to retire the balance of the Company’s original valuation obligation from the material definitive agreement, representing a shortfall of $56,085, in a convertible promissory note, with terms allowing NPE to convert the note into shares of the Company’s common stock of at a 50% discount to the closing price of the Company’s common stock as of the maturity date. The note was satisfied in full during the year ended December 31, 2020.

 

As of the date of this filing, the Company owes $0 and is in compliance with the terms of the Settlement Agreement . On February 3, 2020, the Company issued NPE a convertible promissory note in the principal amount of $56,085. Additionally, as a result of the Settlement Agreement, the Company became liable to pay NPE its 5% portion equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE.

 

Of the total amount due and payable by the Company with regards to the NPE joint venture agreement as of the date of this filing, the Company owes $75,000 and is in breach of the Settlement and Release of All Claims Agreement with NPE. On February 3, 2020, the Company issued a convertible promissory note in the principal amount of $56,085.15 to NPE. Additionally, as a result of the Company’s settlement agreement with NPE, the Company became liable to pay NPE its 5% portion equal to $25,902 of the regulatory charges to the City of Lynwood and the State of California to transfer the cannabis licenses back to NPE. To date, the Company has not paid this amount and it is due and owing.

Brazilian Joint Ventures

 

On September 30, 2020, the Company entered into two joint venture agreements (the “Joint Venture Agreements”) with Marco Guerrero, a director of the Company (“Guerrero”) and related party, to form joint ventures in Brazil and in Uruguay to produce, manufacture, market and sell the Company’s hempSMART™ products in Latin America and to develop and sell hempSMART™ products globally. The Joint Venture Agreements contain equal terms for the formation of the joint venture entities in Uruguay and Brazil. The Brazilian joint venture, HempSmart Produtos Naturais Ltda. (“HempSmart Brazil”), will be headquartered in São Paulo, Brazil. The Uruguayan joint venture, Hempsmart Uruguay S.A.S. (“HempSmart Uruguay”), will be headquartered in Montevideo, Uruguay.

Pursuant to the Joint Venture Agreements, the Company acquired a 70% equity interest in both HempSmart Brazil and HempSmart Uruguay, with a minority 30% equity interest in both HempSmart Brazil and HempSmart Uruguay being held by newly formed entities controlled by Guerrero. Pursuant to the Joint Venture Agreements, the Company agreed to provide capital in the amount of $50,000 to both HempSmart Brazil and HempSmart Uruguay, for a total capital outlay obligation of $100,000. It is expected that the proceeds of the initial capital contribution will be used for contracting with third-party manufacturing facilities in Brazil and Uruguay and related infrastructure and employment of key personnel. As of June 30, 2021, the Company has not initiated the capital contribution but is pending to be done in the third quarter.

 

 

22 
 
 

 

The boards of directors of HempSmart Brazil and HempSmart Uruguay will consist of three directors, elected by the joint venture partners. Pursuant to the Joint Venture Agreements, the Company agreed to license, on a royalty-free basis, certain of its intellectual property regarding its existing products to HempSmart Brazil and HempSmart Uruguay to enable the joint ventures to manufacture and sell its products in Brazil, Uruguay, and for export to other Latin American countries, the United States, and globally in accordance with the terms of the Joint Venture Agreements.

 

In addition, as majority partner, in the event a joint venture is frustrated in its intent or purpose, the Company may trigger a compulsory buy-sell procedure pursuant to which the Company could pursue a sale of all or substantially all of the joint venture. Subject to certain exceptions, the joint venture partners may not transfer their interests in HempSmart Brazil and HempSmart Uruguay.  

 

Cannabis Global, Inc. 

 

Joint Venture

 

On May 12, 2021, the Company entered into a joint venture agreement with Cannabis Global, Inc. (“Cannabis Global”) pursuant to which the Company will invest up to $250,000 into a newly formed entity (“MCOA Lynwood”) and Cannabis Global, through Natural Plant Extracts of California, Inc. (“Natural Plant”), an entity in which Cannabis Global owns a majority interest, will operate a regulated and licensed laboratory to manufacture various cannabis products in the State of California. As of June 30, 2021, the Company has invested $115,000.

Share Exchange

 

On September 30, 2020, the Company entered into a securities exchange agreement with Cannabis Global pursuant to which the Company issued 650,000,000 shares of its common stock to Cannabis Global in exchange for 7,222,222 shares of Cannabis Global common stock. In addition, the Company and Cannabis Global entered into a lock-up leak-out agreement which contains certain restrictions with respect to the sales of such securities.

Eco Innovation Group Inc. – Share Exchange

 

On February 26, 2021, the Company entered into a Share Exchange Agreement with Eco Innovation Group, Inc., a Nevada corporation quoted on OTC Markets Pink (“ECOX”) dated February 26, 2021, to acquire the number of shares of ECOX’s common stock, par value $0.001, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of Company common stock, par value $0.001, equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date (the “Share Exchange Agreement”). For both parties, the Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the Share Exchange Agreement to fall below $650,000. As of June 30, 2021, the Company owed ECOX and additional 64,621,893 with an estimated value of $394,194 related to the ECOX Share Exchange Agreement. The investment balance is $650,000, with a liability of $394,194 included in subscriptions payable related to the value of the additional shares to be issued. The Company recognized a loss of $394,194 related to the shares to be issued.

Complementary to the Share Exchange Agreement, the Company and ECOX entered into a Lock-Up Agreement dated February 26, 2021 (the “Lock-Up Agreement”), providing that the shares of common stock acquired pursuant to the Share Exchange Agreement shall be subject to a lock-up period preventing its sale for a period of 12 months following issuance and limiting the subsequent sale to aggregate maximum sale value of $20,000 per week, or $80,000 per month.

For a period of two years following the Effective Date, at the closing of each fiscal quarter, should the per-share closing price of the common shares of the same class as the Shares or the Exchange Shares, as quoted by the OTC Markets for the last day of the relevant fiscal quarter, decrease below original issuance value with the effect that the aggregate value of the Shares or the Exchange Shares at the fiscal quarter close would be lower than $650,000, then either MCOA, in the case of the Shares, or ECOX, in the case of the Exchange Shares, shall issue the other party the number of shares of common stock necessary to cause the aggregate value of the Shares or the Exchange Shares, as applicable, be $650,000 as of the end of the relevant fiscal quarter. The parties shall irrevocably instruct their respective transfer agents to reserve and maintain authorized and unissued common stock in a reserve account designated for the purpose of issuing such shares pursuant to this share exchange adjustment provision. Such share reserve accounts shall be maintained with a number of authorized and unissued common stock not less than three (3) times the number of Shares or Exchange Shares, as the case may be, that are issued pursuant to the Share Exchange Closing.

 

On February 24, 2021, the closing price of the Company’s common stock was $0.0155, so that the number of shares of Company common stock issuable to ECOX under the Share Exchange Agreement is 41,935,484. As a result of the transactions pursuant to the Share Exchange Agreement, the Company will have 4,179,073,945 shares of common stock outstanding, with the shares issued to ECOX pursuant to the Share Exchange Agreement representing 1.00% of the Company’s outstanding shares.

 

For the quarter ended June 30, 2021, the Company recorded a Loss on Equity Investment and corresponding increase in Subscriptions Payable of $394,194 to address the decline in the Company's stock price from the original issuance price of $.0155.

 

 

 

23 
 
 

 

 

 

 

 

MARIJUANA COMPANY OF AMERICA, INC.

INVESTMENT ROLL-FORWARD

AS OF JUNE 30, 2021

 

 

                                          
   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Beginning balance @12-31-16  $   $             $        $   $   $             $        $ 
                                                                       
Investments made during 2017   3,049,275    10,775              100,000         250,000    1,188,500    1,500,000                        
                                                                       
Quarter 03-31-17 equity method Loss                                                                    
                                                                       
Quarter 06-30-17 equity method Loss                                                                    
                                                                       
Quarter 09-30-17 equity method Loss   (375,000)                                 (375,000)                             
                                                                       
Quarter 12-31-17 equity method accounting   313,702                                  313,702                              
                                                                       
Impairment of Investment in 2017   (2,292,500)                                (792,500)   (1,500,000)                       
Balances as of 12/31/17  $695,477.00   $10,775.00   $   $   $100,000.00   $   $250,000.00   $334,702.00   $   $   $   $   $   $ 

 

 

24 
 
 

 

 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Investments made during 2018   986,654    986,654                                                            
                                                                       
Quarter 03-31-18 equity method Loss   (37,673)                                 (37,673)                             
                                                                       
Quarter 06-30-18 equity method Loss   (111,043)                                 (11,043)                             
                                                                       
Quarter 09-30-18 equity method Loss   (10,422)                  (10,422)                                            
                                                                       
Quarter 12-31-18 equity method Loss   (31,721)   (31,721)                                                          
                                                                       
Moneytrac investment reclassified to Short-Term investments   (250,000)                            (250,000)                       250,000         250,000 
                                                                       
Unrealized gains on trading securities - 2018                                                         560,000         560,000 
                                                                       
Impairment of investment in 2018   (933,195)   (557,631)             (89,578)             (285,986)                             
Balance @12-31-18  $408,077   $408,077   $   $   $   $   $   $   $   $   $   $810,000   $   $ 

 

 

 

25 
 
 

 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
Investments made during quarter ended 03-31-19   129,040    129,040                                                             
                                                                       
Quarter 03-31-19 equity method Loss   (59,541)   (59,541)                                                            
                                                                       
Unrealized gains on trading securities - quarter ended 03-31-19                                                          (135,000)       $(135,000)
                                                                       
Balance @03-31-19  $477,576   $477,576   $   $   $   $   $   $   $   $   $   $675,000   $   $(135,000)
                                                                       
Investments made during quarter ended 06-30-19  $3,157,234   $83,646                                      $3,000,000   $73,588                
                                                                       
Quarter 06-30-19 equity method Income (Loss)  $(171,284)  ($141,870)                                     $(6,291)  $(23,123)               
                                                                       
Unrealized gains on trading securities - quarter ended 06-30-19  $                                                      (150,000)       $(150,000)
                                                                       
Balance @06-30-19  $3,463,526   $419,352   $   $   $   $   $   $   $   $2,993,709   $50,465   $525,000   $   $(285,000)

 

 

26 
 
 

 

 

 

 

 

   INVESTMENTS  SHORT-TERM INVESTMENTS
                                           
   TOTAL 

Global

Hemp

 

Cannabis

Global

        Lynwood     Bougainville Ventues,  Gate C Research  Natural Plant    

TOTAL

Short-Term

  Global Hemp   
   INVESTMENTS  Group  Inc.  ECOX  Benihemp  JV  MoneyTrac  Inc.  Inc.  Extract  Vivabuds  Investments  Group  MoneyTrac
                                                                       
Investments made during quarter ended 09-30-19  $186,263                                                $186,263                
                                                                       
Quarter 09-30-19 equity method Income (Loss)  $122,863   $262,789                                      $(94,987)  $(44,939)               
                                                                       
Sale of trading securities during quarter ended 09-30-19                                                         $(41,667)       $(41,667)
                                                                       
Unrealized gains on trading securities - quarter ended 09-30-19  $                                                      (362,625)       $(362,625)
                                                                       
Balance @09-30-19  $3,772,652   $682,141   $   $   $   $   $   $